Only about one-third of organizations currently use AI across a meaningful share of their clinical trials, yet 92% plan to increase that investment within the next two years — a gap that tells you almost everything about where the industry actually stands versus where it thinks it is heading. WCG’s 2026 Clinical Research Trends and Insights Report lands at precisely that inflection point, framing four operational priorities that will separate organizations that execute from those that continue to improvise: AI and machine learning integration, site and investigator readiness, participant experience, and the logistics of cell and gene therapies.
The site readiness finding deserves more attention than it typically receives. An ICON survey of more than 100 principal investigators conducted in mid-2025 found that 55% of respondents reported site activation taking longer than five months after selection. That is not a technology problem. It is a design and engagement problem, and WCG’s report treats readiness as a continuous organizational asset rather than a pre-trial checklist. The distinction matters because sponsors still commonly invest in site identification and then underinvest in what happens between selection and first patient enrolled, which is precisely where delays compound into protocol deviations and data variability.
The AI thread in the report is more nuanced than most industry commentary. The FDA’s January 2025 draft guidance on AI supporting regulatory decision-making signals that the agency is building an evaluative framework rather than a permissive one, which means governance and auditability are not optional add-ons. WCG positions this correctly: AI is moving from experimental pilots into embedded trial operations, and the organizations that treat governance as infrastructure will have an advantage when regulators begin scrutinizing AI-generated data at submission. The global AI in clinical trials market is projected to reach $3.32 billion in 2026, which means vendor proliferation is accelerating faster than most sites can evaluate tools rigorously.
The report’s participant experience section makes an argument that is still underappreciated operationally: moving from participant-centric design (a framing exercise) to participant-driven design (an actual structural change) improves retention and data quality simultaneously. These are not soft outcomes. Retention failures are one of the most reliable predictors of trial extension costs. The single concrete marker to track as 2026 progresses is whether sponsors begin tying site readiness scores to contract renewal and payment milestones, because that financial lever is what finally converts WCG’s readiness-as-asset framing from a recommendation into an industry norm.
Source link: https://cms.centerwatch.com/insights/wcg-2026-clinical-research-trends-insights-report/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
